Most monoclonal antibodies (mAbs) or their derivatives are used in cancer immunotherapy to target tumor antigens present on the cell surface, such as EGFR, HER2, vascular endothelial growth factor receptor 2 (VEGFR-2), and programmed death-ligand 1 (PD-L1). Here, KDR is linked to cancer.